T7-010

T7-010 is an investigational, orally bioavailable small molecule inhibitor developed by T7 Therapeutics for the treatment of autoimmune and inflammatory diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The drug specifically targets the CD6-ALCAM (Activated Leukocyte Cell Adhesion Molecule) pathway, which is critical for T-cell costimulation, activation, and trafficking into inflamed tissues. By binding to CD6, a glycoprotein expressed on the surface of T cells, T7-010 prevents its interaction with its ligand ALCAM, thereby dampening the pathogenic T-cell responses that drive chronic inflammation. As a small molecule, T7-010 is designed to provide a more convenient oral alternative to existing injectable monoclonal antibody therapies that target the same pathway.